Last Price$1.03Cboe Previous Close - Real-Time Last Sale as of 4:01PM ET 6/24/22
Cboe Real-Time Quotes
Today's Change0(0.00%)
Bid (Size)$1.05 (69)
Ask (Size)$1.07 (4)
Day Low / HighN/A - N/A
Volume10.5 M

View Biotechnology IndustryPeer Comparison as of 06/24/2022


Curis Inc ( NASDAQ )

Price: $1.03
Change: +0.005 (0.49%)
Volume: 10.5 M
4:01PM ET 6/24/2022

Fortress Biotech Inc ( NASDAQ )

Price: $0.88
Change: -0.06 (6.09%)
Volume: 7.6 M
4:00PM ET 6/24/2022

Anixa Biosciences Inc ( NASDAQ )

Price: $3.13
Change: -0.08 (2.49%)
Volume: 49.2 K
4:00PM ET 6/24/2022

Surface Oncology Inc ( NASDAQ )

Price: $1.76
Change: -0.03 (1.68%)
Volume: 4.8 M
4:00PM ET 6/24/2022

Dyadic International Inc ( NASDAQ )

Price: $3.22
Change: +0.17 (5.57%)
Volume: 39.1 K
4:00PM ET 6/24/2022

Read more news Recent News

-- Earnings Flash (CRIS) CURIS Posts Q1 Revenue $2.1M, vs. Street Est of $2.55M
4:32PM ET 5/05/2022 MT Newswires


Curis Says FDA Places Partial Clinical Hold on Study of Emavusertib in Patients With B-Cell Malignancies; Shares Down Pre-Bell
8:54AM ET 4/11/2022 MT Newswires

Curis Inc. (CRIS) said Monday the US Food and Drug Administration has placed a partial clinical hold on a phase 1/2 study evaluating emavusertib in...

--B. Riley Lowers Curis' Price Target to $10 from $22, Says Emavusertib on Partial Hold but Still Promising; Keeps Buy Rating
8:25AM ET 4/05/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Top Midday Decliners
1:27PM ET 4/04/2022 MT Newswires

Curis (CRIS) said the US Food and Drug Administration placed a partial clinical hold on its phase 1/2a study of emavusertib to treat leukemia. Shares of...

View all Commentary and Analysis

Curis Inc.'s (CRIS) CEO Jim Dentzer On Q1 2022 Results - Earnings Call Transcript
6:55PM ET 5/05/2022 Seeking Alpha

Curis Inc. (CRIS) CEO James Dentzer on Q4 2021 Results - Earnings Call Transcript
9:58PM ET 2/24/2022 Seeking Alpha

Curis (CRIS) Investor Presentation - Slideshow
6:01PM ET 1/28/2022 Seeking Alpha

Checking In On Curis
2:12PM ET 12/15/2021 Seeking Alpha

Company Profile

Business DescriptionCuris, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA. View company web site for more details
Address128 Spring Street
Lexington, Massachusetts 02421
Number of Employees31
Recent SEC Filing06/02/20228-K
President, Chief Executive Officer & DirectorJames E. Dentzer
Chief Financial & Administrative OfficerWilliam E. Steinkrauss
VP-Technology Management & Intellectual PropertyMark W. Noel
Head-Research & DevelopmentRobert E. Martell

Company Highlights

Price Open$1.05
Previous Close$1.03
52 Week Range$0.70 - 9.04
Market Capitalization$94.9 M
Shares Outstanding91.6 M
SectorHealth Technology
Next Earnings Announcement08/02/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.56
Beta vs. S&P 500N/A
Revenue$10.4 M
Net Profit Margin-490.81%
Return on Equity-54.04%

Analyst Ratings as of 04/04/2022

Consensus RecommendationConsensus Icon
Powered by Factset